Table 2. Patients’ list related to T790M mutate status.
| Patient # | Sex | EGFR status at diagnosis | Prior EGFR-TKIs | Response to prior EGFR-TKIs | T790M status | Concentrations in cfDNA (ng/L) | ||
|---|---|---|---|---|---|---|---|---|
| Re-biopsy tissue (cobas®) | cfDNA (PointMan) | cfDNA (cobas®) | ||||||
| 1 | F | Exon19 deletion | Gefitinib | PR | T790M | T790M | Undecidable | 0.407 |
| 2 | M | Exon19 deletion | Erlotinib | SD | T790M | T790M | Undecidable | 0.391 |
| 3 | M | Exon19 deletion | Erlotinib | PR | T790M | T790M | T790M | 1.316 |
| 4 | F | Exon19 deletion | Erlotinib | PR | T790M | T790M | Undecidable | 1.781 |
| 5 | F | L858R | Gefitinib | PR | T790M | T790M | T790M | 1.083 |
| 6 | F | Exon19 deletion | Erlotinib | PR | T790M | T790M | T790M | 0.396 |
| 7 | F | Exon19 deletion | Erlotinib | SD | T790M | T790M | T790M | 2.623 |
| 8 | M | L858R | Gefitinib | PR | T790M | T790M | T790M | 1.150 |
| 9 | F | Exon19 deletion | Erlotinib | PR | T790M | T790M | Wild | 1.162 |
| 10 | F | Exon19 deletion | Gefitinib | PR | T790M | T790M | T790M | 0.840 |
| 11 | F | Exon19 deletion | Gefitinib | PR | T790M | T790M | Wild | 0.156 |
| 12 | F | Exon19 deletion | Gefitinib | SD | T790M | Wild | Wild | 0.068 |
| 13 | F | Exon19 deletion | Erlotinib | PD | Wild | T790M | Wild | 0.351 |
| 14 | F | Exon19 deletion | Afatinib | PR | Wild | Wild | Wild | 0.273 |
| 15 | M | Exon19 deletion | Erlotinib | SD | Wild | Wild | Wild | 0.416 |
| 16 | M | L858R, A859S | Gefitinib | PR | Wild | Wild | Wild | 0.690 |
| 17 | F | L858R | Gefitinib | PR | Wild | Wild | Wild | 0.391 |
| 18 | M | Exon19 deletion | Erlotinib | PR | Wild | Wild | Wild | 7.520 |
| 19 | M | L858R | Gefitinib | PR | Wild | Wild | Wild | 6.688 |
EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; cfDNA, cell-free DNA; PR, partial response; PD, progressive disease; SD, stable disease.